The Brain

Home > Other > The Brain > Page 19
The Brain Page 19

by Gary L Wenk

Aluminum, 70–72

  Alzheimer’s disease

  amnesia in, 11–12

  anti-inflammatories, 99–100

  defined, 155

  gender differences, 101

  impaired glucose regulation in, 53

  memory loss treatment, 16–18

  neurotransmitter behavior in, 14–16

  neurotrophic factors, 65

  risk factors for, 100–101

  sleep disturbances in, 89

  spice effects, 65–66

  tea extracts in, 63

  Amnesia, 11–12, 155

  Amygdala, 23–28, 99, 155

  Analgesic, 155

  Anandamide, 68

  Anterograde amnesia, 11–12

  Anticholinergic, 155

  Anticonvulsants, 35, 156

  Antidepressants, 29–32, 55

  Anti-inflammatories, 99–100, 109

  Antioxidants, 63, 69, 95, 97–98

  Antipsychotics, 38, 40

  Anxiety, 31–32, 37, 75, 115

  Anxiolytic, 156

  Aphasia, 144

  Arachnoid mater, 118

  Aspirin, 46, 65, 99–100

  Astrocytes, 121–23, 156

  Astrocytes tumors, 121–22

  ATP, 86–87

  Attention, 7–8, 19–20, 92

  Auditory cortex, 143–44

  Autism, 26, 34, 39

  Autonomic nervous system, 12, 156

  Axons, 121, 129–32, 156

  Balance, 104–5

  Basal ganglia, 133

  B.C.E., 156

  Behavior control, 22, 137–38

  Bilateral, 156

  Bile, 78

  Biorhythms, 51–52

  Bipolar disorder, 34–37, 77–78, 151

  Blood–brain barrier, 17, 41, 123–24, 135, 156

  Body temperature rhythms, 75–76, 93

  Botulinum toxin, 17

  Brain-derived neurotrophic factor (BDNF), 61

  Brain generally. see also specific structures

  blood supply to, 122

  decision-making processes, 25

  development of, 3–4, 15, 125–29

  energy expenditures, 1–3, 53

  function efficiency, 131–32

  gender differences in, 127–28

  organization of, 135–36

  sleep effects on, 74–75

  structure, functions of, 2f, 118–22

  trauma to, 119–20

  Broca, Paul, 138

  Broca’s area, 138–39, 156

  Buoyancy, 119

  Caffeine, 41, 45–48, 86–87, 111

  Caloric restriction, 96–98, 106–7

  Carbamazepine, 35

  Carbohydrates, 52–53

  Carbon, carbon dioxide, 94–95

  Central nervous system, 156

  Cerebellum, 151–53, 156

  Cerebral cortex, 119–20, 124–27, 156

  Cerebral hemispheres, 125, 156

  Cerebrospinal fluid, 118–19

  Chiapas Real, 67, 68

  Chocoholism, 69

  Chocolate, 66–70

  Choline supplementation, 16–17

  Chronic traumatic encephalopathy, 120

  Cingulate gyrus, 22, 150–51

  Cinnamon, 65

  Circadian rhythm, 73, 77–78

  Close-talkers, 27

  Clostridium botulinum, 17

  Cocaine, 47–48

  Coffee. see caffeine

  Cognitive enhancers, 111

  Corpus callosum, 127–28, 153–54, 157

  Cortisol, 76

  Cross-modality, 147

  Curcumin, 65–66

  Cytokines, 56, 107–8

  Daydreaming, 142–43

  Deadly nightshade, 13

  Death, 92–93

  Deep brain stimulation, 35

  Default network, 141

  Dementia. see also Alzheimer’s disease

  alcohol and, 100

  aluminum and, 70–72

  anti-inflammatories, 99–100

  defined, 157

  hallucinations in, 147

  impaired glucose regulation in, 53

  obesity, 55–56, 59–60, 63–64, 92, 107–9

  omega-3 fatty acids, 54–55

  sleep disturbances in, 89

  Dementia pugilistica, 120

  Dendrites, 121, 157

  Dendritic spines, 18–19

  Dentate gyrus, 99

  Deodorants, 72

  Depression

  cingulate gyrus in, 151

  described, 27–29

  development of, 32

  incidence of, 28

  serotonin role in, 30, 32–34

  sleep and, 31–32, 77–78

  susceptibility genes, 37

  treatment, 29–31, 115

  Diet. see also food/drug effects

  all-meat, 64

  caloric restriction, 96–98, 106–7

  fats (dietary), 54–55, 59

  high-fat, 52

  Mediterranean, 54

  restriction, 64, 107

  vegetarian/vegan, 33

  vitamins, 49–50, 62

  Dietary restriction, 64, 107

  Dizziness, 105

  Dopamine

  in basal ganglia, 133

  in depression, 30

  food/drug effects, 51, 53, 59–60

  functions of generally, 133

  loss of in Parkinson’s disease, 102–3

  reward system induction, 58, 142–43

  in schizophrenia, 37–38, 40

  Dose–response effect, 44

  Dreams. see sleeping/dreaming

  Drugs. see food/drug effects

  Dura mater, 118, 157

  Electroconvulsive therapy (ECT), 29

  Emotions

  aging effects, 92

  bipolar disorder, 34–37, 77–78, 151

  close-talkers, 27

  depression ( see depression)

  fear, 23–27, 99

  limbic system, 22–23, 158

  purpose of, 21

  schizophrenia ( see schizophrenia)

  staring, response to, 25–26

  Endocannabinoids, 51, 56, 58, 157

  Endorphins, 51, 56–57, 157

  Epileptic seizures, 73, 144–46

  Exercise, 56, 66, 90, 91, 100, 107, 108, 131

  Eyes, 104, 139–42

  Fats (dietary), 54–55, 59

  Fear, 23–27, 99

  Flavonoids, 66–67

  Flight or fight response, 24–25

  Food/drug effects. see also diet

  addiction, 44–45

  aging, 94–96, 105

  antioxidants, 63, 69, 95, 97–98

  biological drive, 57

  blood–brain barrier, 17, 41, 123–24, 156

  caffeine, 41, 45–48, 86–87, 111

  caloric restriction, 96–98, 106–7

  carbohydrates, 52–53

  chocolate, 66–70

  cognitive function, 61–63

  fats, 54–55, 59

  fat/sugar cravings, 59

  feel good, 48–50

  flavonoids, 66–67

  fruits, vegetables, 62–64

  genetics in, 45–46, 59–60

  gut bacteria, 60–61

  high-fat diet, 52

  mechanisms of, 42–44

  nutritional supplements, 112–14

  obesity, 55–56, 59–60, 63–64, 92, 107–9

  overeating, 50–51

  pleasure, 56–58

  precursor-loading, 48–49

  protein, 95

  sleeping/dreaming, 78

  spices, 48, 65–66

  terminology, 42

  time of day, 51–52

  toxins, 70–72

  uptake/excretion, 41–42

  weight reduction, 64

  wine, 66–67

  Free radicals, 96

  Frontal lobes

  amygdala functions, 26

  in bipolar disorder, 34–36

  defined, 120, 157

  dietary restriction effe
cts, 107

  functions of, 136–38

  lucid dreams, 84–85

  myelination, 36–37, 158

  neurotransmitters in, 133

  speech, 138–39, 144, 153–54, 156

  Fruits, vegetables, 62–64

  GABA, 75, 80, 157

  Gage, Thomas, 67

  Gall, Franz, 135–36

  Galvani, Luigi, 29

  Gastrointestinal system, 157

  Ginkgo biloba, 112–14

  Glia, 121

  Glucose, 44–45, 52–53, 58–59, 78

  Glutamate

  defined, 157

  hallucinations and, 148

  impaired function in disease, 15–16

  in memory formation, 13–15

  in schizophrenia, 37–38

  seizures, 73, 144–46

  Glycogen, 78

  Gray matter, 157

  Gyrus (gyri), 120, 157

  Hallucinations

  defined, 146–48, 157

  near-death experiences, 122–23

  nutmeg, 48

  in Parkinson’s disease, 103

  in schizophrenia, 38–39

  Hearing, sense of, 104, 143–44

  Hearing voices, 38–39

  Hemoglobin, 95

  Henbane, 13

  Herbal medicines, 112–14

  Heroin, 45, 59

  Hippocampus

  aging effects on, 98–99

  defined, 158

  in depression, 27–28

  dreams, content of, 81–83

  in memory, 6–8, 17–19

  neurotransmitter impaired function, 15–16

  neurotransmitters in, 133

  shrinkage, effects of, 85–86

  Hydrocephalus, 119

  Hypersomnolence, 88

  Hypothalamus, 53, 158

  Ibuprofen, 99–100

  Inflammation, 99–103, 108

  Ingestion analgesia, 57

  Insomnia, 74, 75, 89

  Insula, 22–23

  Insulin, 50, 64, 78

  Interpersonal distance, 27

  Introspection, 137

  Ipsilateral, 158

  Jamais vu, 143

  Jimson weed, 13

  Kleine-Levin Syndrome, 88

  Lamotrigine, 35

  Language, 138–39, 144, 156

  Law of Initial Value, 45–46

  Learning, 5–6, 18

  Leptin, 50

  Limbic system, 22–23, 158

  Lipid solubility, 158

  Lipopolysaccharide, 87

  Lithium salts, 35

  Longevity, 93–94, 101, 128–29

  Long-term potentiation (LTP), 158

  LSD, 147–49

  Lucid dreams, 84–85

  Lying, 137

  Magnesium salts, 69

  Mammal, 158

  Mandrake, 13

  Marijuana, 58

  Maternal obesity, 55–56

  Mediterranean diet, 54

  Memory

  aging effects on, 92, 98–99

  alcohol and, 100

  amnesia, 11–12, 155

  attention, 7–8, 19–20, 92

  autobiographical, 150

  consolidation process, 8

  dendritic spines, 18–19

  emotion in, 7

  false, 10–11

  forgetting, 8–9

  formation, storage of, 6–7, 12–18, 26–27

  fruits, vegetables, 62–63

  hippocampus in, 6–8, 17–19

  in learning, 5–6, 18

  loss, treatment of, 16–18

  nicotine effects, 13, 19–20

  obesity effects on, 108–9

  recall, 9–11

  sensory, 6–8

  short-term, 8

  Memory boosters, 111

  Meninges, 118

  Menopause, 69

  Menstrual cycle, 19, 68–69

  Metabolic syndrome, 52

  Microglial, 158

  Migraines, 31–32, 73

  Miracle cures, 109–12

  Mitochondria, 158

  Monoamine oxidase (MAO), 69–70

  Morphine, 46

  3-MT, 122–23

  Multiple sclerosis, 130–31

  Muscarine, muscarine receptors, 13

  Myelin, 37, 158

  Myelination, 36–37, 103, 158

  Myelin sheaths, 130

  Narcolepsy, 79, 158

  Naturopathy, 114

  Near-death experiences, 122–23

  Neurogenesis, 129

  Neurons

  communication between, 125, 127, 129–30

  defined, 121, 158

  development of, 126–29

  fat/sugar cravings, 59

  flavonoids, 66–67

  loss of in Parkinson’s disease, 102–3

  in memory formation, 13–15

  myelination, 36–37, 103, 158

  neurotrophic factors, 65

  public speaking, 25–26

  sleep effects on, 74–75, 78

  tumors, 122

  Neurotransmitters. see also specific neurotransmitters

  behavior in Alzheimer’s disease, 14–16

  defined, 132–35, 158–59

  in depression, 30

  endocannabinoids, 51, 56, 58, 157

  food/drug effects, 51

  function efficiency, 131–32

  loss of in Parkinson’s disease, 102–3

  in memory formation, 12–13

  memory loss treatment, 16–18

  precursor-loading, 48–49

  receptors, 13, 19–20, 134, 160

  REM atonia, 80–81, 159

  reuptake, 134, 160

  in schizophrenia, 37–38

  in sleeping/dreaming, 78–80

  Neurotrophic factors, 65

  Nicotine, 13, 19–20, 41, 45, 50, 111

  Nicotinic receptors, 19–20

  Non-REM sleep, 79–80, 82, 83, 85, 159

  Norepinephrine, 30, 102–3, 133

  Nutmeg, 48

  Nutritional supplements, 112–14

  Nystagmus, 153, 159

  Obesity, 55–56, 59–60, 63–64, 92, 107–9

  Obsessive compulsive disorder, 22

  Occipital lobes, 120, 139–42, 159

  Omega-3 fatty acids, 54–55

  Oppositional defiant disorder, 37

  Orexin, 51, 79, 159

  Overeating, 50–51

  Ovulation, 19

  Oxygen, 49–50, 94–97, 122

  Parasympathetic nervous system, 159

  Parietal lobes, 120, 149–50, 159

  Parkinson, James, 102

  Parkinson’s disease

  antipsychotics and, 40

  deep brain stimulation, 35

  defined, 159

  described, 102

  neurotrophic factors, 65

  REM behavior disorder and, 81, 160

  risk factors for, 102–3

  spice effects, 65–66

  treatment, 103, 115

  Parkinson’s pugilistica, 120

  Phenethylamine (PEA), 69–70

  Pia mater, 118, 159

  Pill color effects, 116

  Placebo effect, 111–17, 124, 159

  Placebome, 116

  Poikilotherms, 93, 159

  Polyphenols, 63

  Prefrontal cortex, 159

  Presynaptic, 159

  Prevagen, 124

  Progesterone, 19, 69

  Proinflammatory proteins, 32

  Protein, 95

  Protoneurons, 126, 127

  Pseudoscience, 114, 159

  Public speaking, 25–26

  Punch-drunk syndrome, 120

  Quercetin, 63

  Receptors, 13, 19–20, 134, 160

  REM atonia, 80–81, 159

  REM behavior disorder, 81, 160

  REM sleep, 80, 82–87, 89, 93

  Restriction diets, 64, 107

  Resveratrol, 63

  Retina, 104

  Retrograde amnesia, 11

  Reuptake, 134, 160

&nb
sp; Saccadic eye movement, 140

  Salvinorin A, 148

  Schizophrenia

  defined, 36–38, 151

  dopamine in, 37–38, 40

  genetics in, 34

  glutamate in, 37–38

  hallucinations in, 38–39, 147

  incidence of, 28

  nicotinic receptors, 20

  Seizures, 73, 144–46

  Self-reflection, 141–42

  Serotonin

  defined, 160

  in depression, 30, 32–34

  hallucinations and, 147–48

  loss of in Parkinson’s disease, 102–3

  in venom, 43

  Sickness behaviors, 33

  Sleeping/dreaming

  adenosine, 86–87

  aging effects, 89–90

  circadian rhythm, 73, 77–78

  daily rhythm control, 78–80

  daily rhythm disruptions, 76–78

  daily rhythms, 75–76, 85–86

  deprivation, 31, 73–74, 79, 88–89, 110

  described, 73–74

  dreams, 74

  dreams, content of, 81–83

  dreams, time spent in, 85

  dreams of children, 83–84

  dreams of suffocation, 83

  food/drug effects, 78

  gender differences, 82–83, 86

  hormone fluctuations, 76

  importance of, 74–75

  insomnia, 74, 75, 89

  lucid dreams, 84–85

  narcolepsy, 79, 158

  nondream (slow wave), 74

  non-REM, 79–80, 82, 83, 85, 159

  prolonged cycle, 87–88

  quality, efficiency, 86, 90, 92

  REM, 80, 82–87, 89, 93

  REM atonia, 80–81, 159

  REM behavior disorder, 81, 160

  wakefulness, 74

  Smoking, 13, 19–20, 92

  Social cues, 26

  Sodium benzoate, 65

  Speech, 138–39, 144, 153–54, 156

  Spices, 48, 65–66

  SSRIs (selective serotonin reuptake inhibitors), 30–31

  Statins, 76

  Stress, chronic, 25

  Strokes, 113, 139

  Sugar, 44–45, 52–53, 58–59, 78

  Sulcus (sulci), 120, 160

  Sympathetic nervous system, 160

  Synapses, 15, 134, 160

  Synaptic vesicles, 160

  Synesthesia, 148–49, 160

  Taste sense, 51, 105

  Telomeres, 94

  Temporal lobes, 5, 120, 143–46, 160

  Testosterone, 94, 96–97

  Touch sense, 105–6

  Tryptophan, 33, 48–49

  Turmeric, 65–66

  Tyramine, 69–70

  Ursolic acid, 63–64

  Vagus nerve, 17

  Valproate, 35

  Vegetarian/vegan diet, 33

  Vertigo, 105

  Vestibular system, 104–5

  Visual system, 104, 139–42

  Vitamins, dietary, 49–50, 62

  Weight reduction, 64

  Wernicke’s area, 144, 160

  White matter, 160

  Willow tree bark, 65

  Wine, 66–67

 

 

 


‹ Prev